<span style="font-size:11.0pt;font-family: "Times New Roman";mso-fareast-font-family:"Times New Roman";mso-bidi-font-family: Mangal;mso-ansi-language:EN-GB;mso-fareast-language:EN-US;mso-bidi-language: HI" lang="EN-GB">Virtual screening and docking exploration on estrogen receptor: An <i>in silico</i> approach to decipher novel anticancer agents</span>

Abstract

Breast cancer is a prominent disorder that affects mostly mid aged women with a high intensity, upsetting every ninth women of ten. The available drugs and treatments fall back as they do not completely eradicate the cancerous cells from body. Hence, newer and more effective drugs and treatments against breast cancer are the need-of-hour. The increased level of estrogen within body increases the chance of breast cancer, whereas the regular concentration plays significant role in normal cell functioning. Melatonin is popularly used as an anti-estrogenic compound, whereas violacein an active secondary metabolite secreted by bacteria like ‘<i>Chromobacterium violaceum</i><span style="mso-bidi-font-style:italic">’ has strong structural similarity with melatonin and, thus, possess latency of being tested for its anti-cancerous activity. In the current study, docking and virtual screening was utilized to prove the fact that violacein and similar compounds can bind more efficiently to estrogen receptor than that of melatonin and, hence, has potential to emerge as lead anti-estrogenic compound in treatment of breast cancer.

</span>